黄葵缓释片的研制及体外释放度的考察  

Study on Preparation of Huangkui Sustained Release Tablets and Its Release in vitro

作　　者：谢涛[1] 刘汉清[1] 张明[1] 蒋鸣[1] 

机构地区：[1]南京中医药大学,江苏南京210046

出　　处：《现代中药研究与实践》2010年第2期50-53,共4页Research and Practice on Chinese Medicines

摘　　要：目的研制黄葵缓释片,并考察其体外释放度。方法采用混合骨架材料制备黄葵缓释片,以人工胃液为溶出介质,采用紫外分光光度法考察缓释片体外释放度。结果筛选得到缓释片最佳处方为:TFA25%,HPMC(K4M)55%,EC 5%,Lactose 15%,Mg stearate 1%。结论黄葵缓释片的制备工艺较简单稳定、重现性好,制得的缓释骨架片具有较理想的缓释作用。Objective To study preparation of Huangkui sustained-release tablets and its release in vitro. Methods Mixed matrix material was used to prepare Huangkui sustained-release tablets, and UV method was used to examine the release of tablets in vitro. Results The screening was the best prescription for sustainedrelease tablets,that were TFA 250, HPMC（K4M） 55%, EC 5%, Lactose 15% and Magnesium stearate 1%. Conclusion Preparation process of Huangkui sustained-release tablets is relatively simple and stable, with good reproducibility obtained with the sustained-release matrix tablets release the role better.

关 键 词：黄葵缓释片 紫外分光光度法 释放度 

分 类 号：R944.4[医药卫生—药剂学]